ArticleJTO clinical and research reports2024

The Whole Picture of First-Line Osimertinib for EGFR Mutation-Positive Advanced NSCLC: Real-World Efficacy, Safety, Progression Pattern, and Posttreatment Therapy (Reiwa Study).

Kageaki Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.